Annals of Hematology

, Volume 89, Issue 9, pp 905–912

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

  • Sung Sook Lee
  • Cheolwon Suh
  • Bong-Seog Kim
  • Jooseop Chung
  • Young-Don Joo
  • Hun-Mo Ryoo
  • Young Rok Do
  • Jong-Youl Jin
  • Hye Jin Kang
  • Gyeong-Won Lee
  • Moon Hee Lee
  • Hyeok Shim
  • Kihyun Kim
  • Sung-Soo Yoon
  • Soo Mee Bang
  • Ho Young Kim
  • Je-Jung Lee
  • Jinny Park
  • Dong Soon Lee
  • Jae-Hoon Lee
  • the Korean Multiple Myeloma Working Party (KMMWP)
Original Article

DOI: 10.1007/s00277-010-0943-z

Cite this article as:
Lee, S.S., Suh, C., Kim, BS. et al. Ann Hematol (2010) 89: 905. doi:10.1007/s00277-010-0943-z

Abstract

We conducted a phase 2 study with bortezomib, doxorubicin, and dexamethasone (PAD) followed by thalidomide and dexamethasone (TD) in patients with relapsed multiple myeloma (MM). Forty patients were enrolled between November 2005 and October 2007, with follow-up continuing until January 2009. Efficacy could be assessed in 37 patients. The overall response rate to PAD followed by TD was 83.6%: complete response 51.4%, near-complete response 13.4%, very good partial remission 5.4%, and partial response 13.4%. The median follow-up was 27 months (range 13–39). The median progression-free survival (PFS) from the start of treatment was 18 months (95% CI, 9.7–26.2 months), with a 1-year PFS rate of 56.9% and 3-year PFS rate of 25.7%. Median overall survival was 35.1 months (95% CI, 18.5–51.7), with a 1-year survival rate of 75% and 3-year survival rate of 27.3%. One hundred seventy-eight PAD cycles (median 6, range 1–6) in 38 patients were assessable for safety. The most common hematologic toxicity was thrombocytopenia, with grade 3–4 in 35.8%. Sensory neuropathy occurred at grade 2 in 26.3% and grade 3 in 10.3%. Two hundred TD treatment cycles (median 4, range 0–12 cycles) were administered. Most adverse events were of mild degree and manageable. PAD followed by TD in patients with relapsed MM is very effective and tolerable.

Keywords

Bortezomib Doxorubicin Thalidomide Dexamethasone Multiple myeloma Relapse 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Sung Sook Lee
    • 1
  • Cheolwon Suh
    • 2
  • Bong-Seog Kim
    • 3
  • Jooseop Chung
    • 4
  • Young-Don Joo
    • 5
  • Hun-Mo Ryoo
    • 6
  • Young Rok Do
    • 7
  • Jong-Youl Jin
    • 8
  • Hye Jin Kang
    • 9
  • Gyeong-Won Lee
    • 10
  • Moon Hee Lee
    • 11
  • Hyeok Shim
    • 12
  • Kihyun Kim
    • 13
  • Sung-Soo Yoon
    • 14
  • Soo Mee Bang
    • 15
  • Ho Young Kim
    • 16
  • Je-Jung Lee
    • 17
  • Jinny Park
    • 18
  • Dong Soon Lee
    • 14
  • Jae-Hoon Lee
    • 18
    • 19
  • the Korean Multiple Myeloma Working Party (KMMWP)
  1. 1.Yonsei Cancer Center, Severance HospitalSeoulSouth Korea
  2. 2.Asan Medical CenterSeoulSouth Korea
  3. 3.Seoul Veterans HospitalSeoulSouth Korea
  4. 4.Busan National University HospitalBusanSouth Korea
  5. 5.Busan Paik HospitalBusanSouth Korea
  6. 6.Daegu Catholic University HospitalDaeguSouth Korea
  7. 7.Keimyung University, Dongsan Medical CenterDaeguSouth Korea
  8. 8.Bucheon St. Mary’s Hospital, The Catholic University of KoreaSeoulSouth Korea
  9. 9.Korea Institute of Radiological and Medical SciencesSeoulSouth Korea
  10. 10.Gyeongsang National University HospitalJinjuSouth Korea
  11. 11.Inha University HospitalIncheonSouth Korea
  12. 12.Wonkwang University HospitalIksanSouth Korea
  13. 13.Sungkyunkwan University Samsung Medical CenterSeoulSouth Korea
  14. 14.Seoul National University College of MedicineSeoulSouth Korea
  15. 15.Seoul National University Bundang HospitalSeoulSouth Korea
  16. 16.Hallym University Medical CenterSeoulSouth Korea
  17. 17.Chonnam National University Hwasun HospitalGwangjuSouth Korea
  18. 18.Gachon University Gil HospitalIncheonSouth Korea
  19. 19.Division of Hematology/OncologyGachon University Gil HospitalIncheonSouth Korea

Personalised recommendations